It also significantly lowered asthma-related hospitalizations in the anti-IgE group (RR: 0.47, 95% CI: 0.33–0.68, P < 0.0001, I2 = 42.5%) (Supplementary Figure S1B). The gene discussed is IGHE; the disease is asthma.